These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus? Meise U; Kurz M; Fleischhacker WW Schizophr Bull; 1994; 20(1):215-25. PubMed ID: 7910977 [TBL] [Abstract][Full Text] [Related]
26. The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819 [No Abstract] [Full Text] [Related]
27. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR). Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J; Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755 [TBL] [Abstract][Full Text] [Related]
28. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice]. Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726 [TBL] [Abstract][Full Text] [Related]
29. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data. Ladea M; Barbu CM; Juckel G Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648 [TBL] [Abstract][Full Text] [Related]
30. [The course of the first schizophrenic illness. A 5-year catamnesis]. Fähndrich E; Richter S Nervenarzt; 1986 Dec; 57(12):705-11. PubMed ID: 2881221 [No Abstract] [Full Text] [Related]
31. Original research paper. Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. Bole CB; Pišlar M; Šen M; Tavčar R; Mrhar A Acta Pharm; 2017 Mar; 67(1):99-112. PubMed ID: 28231044 [TBL] [Abstract][Full Text] [Related]
32. The role of second-generation antipsychotics in the treatment of psychotic disorders. Jackson CW Am J Health Syst Pharm; 2007 Apr; 64(8):815. PubMed ID: 17420195 [No Abstract] [Full Text] [Related]
33. [Factors related to treatment adherence in schizophrenic patients]. García Cabeza I; Sánchez Díaz EI; Sanz Amador M; Gutiérrez Rodríguez M; González de Chávez M Actas Esp Psiquiatr; 1999; 27(4):211-6. PubMed ID: 10469940 [TBL] [Abstract][Full Text] [Related]
34. Nemonapride for the treatment of schizophrenia. Satoh K; Someya T; Shibasaki M Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292 [No Abstract] [Full Text] [Related]
35. The MATRICS consensus cognitive battery: what we know 6 years later. Green MF; Harris JG; Nuechterlein KH Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630 [No Abstract] [Full Text] [Related]
38. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Kramer MS; Last B; Getson A; Reines SA Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198 [TBL] [Abstract][Full Text] [Related]
39. Early prediction of antipsychotic response in schizophrenia. Correll CU; Malhotra AK; Kaushik S; McMeniman M; Kane JM Am J Psychiatry; 2003 Nov; 160(11):2063-5. PubMed ID: 14594760 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study. Díaz-Marsá M; Sánchez S; Rico-Villademoros F; J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]